Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Deng Biping; Chang Alex Hongsheng; Yang Junfang; Pan Jing; Zhang Xian; Lin Yuehui; Wu Yanan; Deng Zhenling; Lu Peihua; Wu Tong; Liu Zhaoli; Zhang Yue; Tong Chunrong

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

【24h】

Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

机译：低剂量CD19靶向嵌合抗原受体T（CAR-T）细胞免疫疗法在47例难治性B细胞急性淋巴细胞白血病（B-ALL）复发患者中的安全性和有效性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共7页
作者
Deng Biping; Chang Alex Hongsheng; Yang Junfang; Pan Jing; Zhang Xian; Lin Yuehui; Wu Yanan; Deng Zhenling; Lu Peihua; Wu Tong; Liu Zhaoli; Zhang Yue; Tong Chunrong;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) [J] . Deng Biping, Chang Alex Hongsheng, Yang Junfang, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：低剂量CD19靶向嵌合抗原受体T（CAR-T）细胞免疫疗法在47例难治性B细胞急性淋巴细胞白血病（B-ALL）复发患者中的安全性和有效性
2. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS TARGETING THE CD19 ANTIGEN FOR THE TREATMENT OF RELAPSED B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) [J] . Curran Kevin Pediatric blood & cancer . 2014,第Suppla1期

机译：靶向CD19抗原的嵌合抗原受体（CAR）T细胞用于治疗复发的B细胞急性淋巴细胞白血病（B-ALL）
3. Immunotherapy with Autologous Anti-CD19 Chimeric Antigen Receptor T Cells Followed By Allogeneic Hematopoietic Stem Cell Transplantation Has Remarkably Improved Leukemia-Free Survival in Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia [J] . Zhao Yan-Li, Wu Tong, Liu De-Yan, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：自体抗CD19嵌合抗原受体T细胞的免疫治疗，随后进行异基因造血干细胞移植，显着改善了难治性/复发性B细胞急性淋巴细胞白血病中的无白血病生存率。
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia [O] . Yiyun Wang, Yingying Yang, Ruimin Hong, 2020

机译：复发/难治性急性淋巴细胞白血病患者CD19单型和CD19 / CD22双特异性嵌合抗原受体T细胞治疗的回顾性比较
6. A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia [O] . Yongxian Hu, Jiasheng Wang, Guoqing Wei, 2018

机译：复发/难治急性淋巴细胞白血病患者同种异体和自体嵌合抗原受体T细胞疗法的回顾性比较

Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

著录项

相似文献

相关主题

期刊订阅